[1] |
ZHANG Yujia, MA Li.
Advances and controversies in new techniques of breast pathology
[J]. China Oncology, 2025, 35(3): 283-290.
|
[2] |
LIN Jialin, WANG Wenna, XU Binghe.
Current status and future perspectives of antibody-drug conjugates in breast cancer therapy
[J]. China Oncology, 2025, 35(2): 154-166.
|
[3] |
WANG Shanshan, YE Dingwei, YANG Li, CHENG Fan, YANG Tiejun, ZHANG Xiaoping, YU Zhixian, ZHANG Qingyun, YANG Yong.
Correlation of HER2 expression and clinicopathological characteristics in patients with urothelial carcinoma in China
[J]. China Oncology, 2024, 34(11): 1011-1019.
|
[4] |
ZHAO Junxiu, ZHU Yi, SONG Xiaoyu, ZHE Chao, XIAO Yuhan, LIU Yunduo, LI Linhai, XIAO Bin.
Circ-0007766 acts as a miR-1972 sponge to promote breast cancer cell migration and invasion via upregulation of HER2
[J]. China Oncology, 2024, 34(10): 915-930.
|
[5] |
JIANG Lin, LIU Qiying, JIA Liqing, ZHANG Jing, CHANG Heng, XUE Tian, REN Min, BAI Qianming, ZHU Xiaoli, ZHOU Xiaoyan.
Retrospective study on MGMT methylation status and its clinical significance in gliomas
[J]. China Oncology, 2023, 33(8): 740-750.
|
[6] |
KANG Yinnan, CHEN Shun, XIE Youcheng, ZHENG Ying, HE Yujing, LI Chuyi, YU Xiaohui.
Application and research progress of antibody drug conjugates in HER2 positive advanced gastric cancer
[J]. China Oncology, 2023, 33(8): 790-800.
|
[7] |
DIAO Xinfeng, LI Xinmao, HOU Liang, WEI Zhixuan.
WTAP promotes proliferation and aerobic glycolysis via regulating m6A modification of BMI1 mRNA
[J]. China Oncology, 2023, 33(7): 655-663.
|
[8] |
ZHOU Cong, HE Lina, CHENG Xiaojiao, HUANG Tinglei, TU Shuiping.
Effect of RSPO3 on inhibiting the growth of colorectal cancer transplanted tumors and increasing NK cell infiltration in vivo
[J]. China Oncology, 2023, 33(7): 664-672.
|
[9] |
WANG Ruoxi, JI Peng, GONG Yue, CHEN Sheng.
Response rate and clinical outcome of HER2-low breast cancer after neoadjuvant therapy: a single-center retrospective study
[J]. China Oncology, 2023, 33(7): 686-692.
|
[10] |
YANG Wenxiao, GUO Linwei, LING Hong, HU Xin.
Characterization of immune microenvironment identifies prognostic and immunotherapy benefit for trastuzumab-based therapy
[J]. China Oncology, 2023, 33(5): 484-498.
|
[11] |
LIU Yang, HU Yiyang, LIU Yueping, NIU Shuyao, DING Pingan, TIAN Yuan, GUO Honghai, YANG Peigang, ZHANG Ze, ZHENG Tao, TAN Bibo, FAN Liqiao, LI Yong, ZHAO Qun.
The value of artificial intelligence-assisted technology in HER2 assessmentof gastric cancer patients receiving neoadjuvant chemotherapy
[J]. China Oncology, 2023, 33(4): 377-387.
|
[12] |
SHAO Zhibo, YANG Benlong, WU Jiong.
Progress of important clinical trials of breast cancer in China in 2022
[J]. China Oncology, 2023, 33(2): 103-109.
|
[13] |
WANG Xueer, WANG Yongsheng.
The research advances and the clinical value of antibody-drug conjugate from molecular subtyping of breast cancer in the era of "precision medicine"
[J]. China Oncology, 2023, 33(12): 1073-1082.
|
[14] |
HONG Yaping, HUANG Yunjian, HUANG Zhangzhou, CHEN Shengjia, ZHONG Qiaofeng, ZENG Hongfu, ZHUANG Wu.
Efficacy and prognostic predictors of first-generation EGFR TKI-targeted therapy in patients with EGFR-mutated advanced non-small cell lung cancer
[J]. China Oncology, 2022, 32(7): 624-634.
|
[15] |
LIU Jianlan, CHEN Daishi, HU Hong, ZHOU Dongxian, HU Jintao.
Predictors of response to neoadjuvant treatment and changes to HER2 status in HER2-positive invasive breast cancer
[J]. China Oncology, 2022, 32(5): 417-426.
|